Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · IEX Real-Time Price · USD
9.32
-0.01 (-0.11%)
At close: Jul 19, 2024, 4:00 PM
9.42
+0.10 (1.07%)
Pre-market: Jul 22, 2024, 8:49 AM EDT
Larimar Therapeutics Employees
Larimar Therapeutics had 42 employees as of December 31, 2023. The number of employees increased by 16 or 61.54% compared to the previous year.
Employees
42
Change (1Y)
16
Growth (1Y)
61.54%
Revenue / Employee
n/a
Profits / Employee
-$1,073,262
Market Cap
594.63M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 42 | 16 | 61.54% |
Dec 31, 2022 | 26 | -5 | -16.13% |
Dec 31, 2021 | 31 | 3 | 10.71% |
Dec 31, 2020 | 28 | 12 | 75.00% |
Dec 31, 2019 | 16 | - | - |
Related Stocks
Company Name | Employees |
---|---|
ZimVie | 2,600 |
Emergent BioSolutions | 1,600 |
Adaptive Biotechnologies | 709 |
Surmodics | 376 |
Allogene Therapeutics | 233 |
ProKidney | 163 |
Annexon | 71 |
Celcuity | 55 |
LRMR News
- 7 weeks ago - Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia - GlobeNewsWire
- 2 months ago - Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia - GlobeNewsWire
- 2 months ago - Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results - GlobeNewsWire
- 4 months ago - Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development - GlobeNewsWire
- 4 months ago - Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia - GlobeNewsWire
- 4 months ago - Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference - GlobeNewsWire
- 5 months ago - Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 5 months ago - Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock - GlobeNewsWire